Avalo Therapeutics, Inc.
AVTXCIK 0001534120 · last filing Jul 2, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
4,654 bought / 4,654 sold
net +0 sh · −$42.4K
- buys
- 2
- sells
- 1
- insiders active
- 1
Filing tape
Filed Thu, Jul 2, 2026
- ±0
Philip Ron M — Director
- Granted69Stock Option (Right to Buy)@ $15.04→ 69 held
- −0 sh · $42.4K
Doyle Mittie — Chief Medical Officer
- Exercised2,875Common Stock@ $12.65→ 54,651 held
- Exercised1,779Common Stock@ $8.04→ 56,430 held
- Sold4,654Common Stock@ $20.00→ 51,776 held
- Exercised2,875Stock Option (Right to Buy)→ 125,750 held
- Exercised1,779Stock Option (Right to Buy)→ 115,092 held
- ±0
Jain Rita — Director
- Granted1,080Stock Option (Right to Buy)@ $15.04→ 1,080 held
- ±0
Lind Kevin Robert — Director
- Granted1,105Stock Option (Right to Buy)@ $15.04→ 1,105 held
Insiders on this tape
- Philip Ron MDirector
- Doyle MittieChief Medical Officer
- Jain RitaDirector
- Lind Kevin RobertDirector
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.